Axicabtagene-ciloleucel/tisagenlecleucel: Cytokine release syndrome.

In a retrospective study of 329 patients with aggressive B cell lymphoma, two adult patients developed cytokine release syndrome (CRS) during treatment with tisagenlecleucel or axicabtagene-ciloleucel. Both patients ultimately died as a result of CRS. The study does not provide specific information about the routes, dosages, or duration of the treatments that led to the onset of CRS. [Extracted from the article]